Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Deepa Jeyakumar

Showing results (31-40 of 42) with videos related to

Pageof 5
Sort By:
Leukemia & Lymphoma|October 6, 2023
Measurable residual disease conversion rate with consolidation chemotherapy in acute myeloid leukemiaDaria Gaut, Caspian Oliai, Jonathan Boiarsky, et al.
Blood Advances|November 2, 2022
Dasatinib/prednisone induction followed by blinatumomab/dasatinib in Ph+ acute lymphoblastic leukemiaAnjali S Advani, Anna Moseley, Kristen M O'Dwyer, et al.
Leukemia|August 21, 2023
Glasdegib plus intensive or non-intensive chemotherapy for untreated acute myeloid leukemia: results from the randomized, phase 3 BRIGHT AML 1019 trialMikkael A Sekeres, Pau Montesinos, Jan Novak, et al.
Blood Neoplasia|September 8, 2025
A phase 1 study of IO-202, an anti-LILRB4 antibody, in chronic myelomonocytic leukemia and acute myeloid leukemiaAhmed Aribi, Gabriel N Mannis, Yazan F Madanat, et al.
Blood Neoplasia|June 2, 2025
Devimistat plus chemotherapy vs chemotherapy alone for older relapsed or refractory patients with AML: results of the ARMADA trialTimothy S Pardee, Bayard L Powell, Richard A Larson, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|September 13, 2023
Tolerability and Efficacy of the Anticluster of Differentiation 47 Antibody Magrolimab Combined With Azacitidine in Patients With Previously Untreated AML: Phase Ib ResultsNaval G Daver, Paresh Vyas, Suman Kambhampati, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|March 8, 2023
Magrolimab in Combination With Azacitidine in Patients With Higher-Risk Myelodysplastic Syndromes: Final Results of a Phase Ib StudyDavid A Sallman, Monzr M Al Malki, Adam S Asch, et al.
Journal for Immunotherapy of Cancer|August 30, 2023
Impact of prior therapies and subsequent transplantation on outcomes in adult patients with relapsed or refractory B-cell acute lymphoblastic leukemia treated with brexucabtagene autoleucel in ZUMA-3Bijal D Shah, Ryan D Cassaday, Jae H Park, et al.
Leukemia|March 20, 2025
Three-year analysis of adult patients with relapsed or refractory B-cell acute lymphoblastic leukemia treated with brexucabtagene autoleucel in ZUMA-3Bijal D Shah, Ryan D Cassaday, Jae H Park, et al.
Journal of Hematology & Oncology|December 9, 2022
Two-year follow-up of KTE-X19 in patients with relapsed or refractory adult B-cell acute lymphoblastic leukemia in ZUMA-3 and its contextualization with SCHOLAR-3, an external historical control studyBijal D Shah, Armin Ghobadi, Olalekan O Oluwole, et al.
Pageof 5

Showing results (31-40 of 42) with videos related to

Sort By:
Pageof 5
Leukemia & Lymphoma|October 6, 2023
Measurable residual disease conversion rate with consolidation chemotherapy in acute myeloid leukemiaDaria Gaut, Caspian Oliai, Jonathan Boiarsky, et al.
Blood Advances|November 2, 2022
Dasatinib/prednisone induction followed by blinatumomab/dasatinib in Ph+ acute lymphoblastic leukemiaAnjali S Advani, Anna Moseley, Kristen M O'Dwyer, et al.
Leukemia|August 21, 2023
Glasdegib plus intensive or non-intensive chemotherapy for untreated acute myeloid leukemia: results from the randomized, phase 3 BRIGHT AML 1019 trialMikkael A Sekeres, Pau Montesinos, Jan Novak, et al.
Blood Neoplasia|September 8, 2025
A phase 1 study of IO-202, an anti-LILRB4 antibody, in chronic myelomonocytic leukemia and acute myeloid leukemiaAhmed Aribi, Gabriel N Mannis, Yazan F Madanat, et al.
Blood Neoplasia|June 2, 2025
Devimistat plus chemotherapy vs chemotherapy alone for older relapsed or refractory patients with AML: results of the ARMADA trialTimothy S Pardee, Bayard L Powell, Richard A Larson, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|September 13, 2023
Tolerability and Efficacy of the Anticluster of Differentiation 47 Antibody Magrolimab Combined With Azacitidine in Patients With Previously Untreated AML: Phase Ib ResultsNaval G Daver, Paresh Vyas, Suman Kambhampati, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|March 8, 2023
Magrolimab in Combination With Azacitidine in Patients With Higher-Risk Myelodysplastic Syndromes: Final Results of a Phase Ib StudyDavid A Sallman, Monzr M Al Malki, Adam S Asch, et al.
Journal for Immunotherapy of Cancer|August 30, 2023
Impact of prior therapies and subsequent transplantation on outcomes in adult patients with relapsed or refractory B-cell acute lymphoblastic leukemia treated with brexucabtagene autoleucel in ZUMA-3Bijal D Shah, Ryan D Cassaday, Jae H Park, et al.
Leukemia|March 20, 2025
Three-year analysis of adult patients with relapsed or refractory B-cell acute lymphoblastic leukemia treated with brexucabtagene autoleucel in ZUMA-3Bijal D Shah, Ryan D Cassaday, Jae H Park, et al.
Journal of Hematology & Oncology|December 9, 2022
Two-year follow-up of KTE-X19 in patients with relapsed or refractory adult B-cell acute lymphoblastic leukemia in ZUMA-3 and its contextualization with SCHOLAR-3, an external historical control studyBijal D Shah, Armin Ghobadi, Olalekan O Oluwole, et al.
Pageof 5